Hamed Nayeb-Hashemi et al. indicated that FGL1 serves as a tumor suppressor in HCC, knockout FGL1 expression strengthens the Akt/mTOR signaling pathway, thus supporting FGL1 as a therapeutic target for HCC 33. The gene discussed is MTOR; the disease is hepatocellular carcinoma.